Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
OBJECTIVE
The aim of this study was to assess the consumption of anti-haemophilic drugs by adults and children with severe haemophilia A or B (residual activity of FVIII or FIX < or =2%) and to quantify the average direct medical costs.


METHODS
A retrospective multicentre cost-of-illness study from the perspective of French national health insurance system. The costs include only the use of clotting factors.


METHODS
Consumption was expressed in UI/kg/year and costs in euros/kg/year.


RESULTS
From January 1, 2001 to December 31, 2002, data from 81 adults and 30 children with severe haemophilia A (n = 92) or B (n = 19) and included in the "SNH" were collected and analysed. A coagulation factor inhibitor was present in 10 patients (9%). Four of them were high responders. Mean age and body weight were respectively 28 +/- 17 years and 58 +/- 24 kg. Except for one adult patient, all (99%) had outpatient treatment, 44 patients (40%) were hospitalized and treated by recombinant or/and plasma-derived FVIII or FIX or/and rFVIIa. Overall median annual consumption of anti-haemophilic drugs per patient was estimated at 1,333 UI/kg, with a median cost-of-illness of 1,156 euros/kg. Patients with severe haemophilia B consumed more than patients with severe haemophilia A, though not significantly (P = 0.096), with a median of 2,167 vs. 1,100 UI/kg/year and a median cost of 1,760 vs. 917 euros/kg/year (P = 0.13). Children consumed respectively more than adults (P = 0.008), with a median of 3,204 vs. 1,106 UI/kg/year and a median cost of 2,614 vs. 913 euros/kg/year (P = 0.012). The median cost for patients with an inhibitor was 3,291 euros/kg/year, approximately threefold higher than that of patients without an inhibitor (926 euros/kg/year) (P = 0.022).


CONCLUSIONS
It suggests a higher consumption and cost of anti-haemophilic drugs among children when compared to adults. Haemophilia B patients did not consume significantly more than haemophilia A patients, whereas the consumption and cost for patients with or without inhibitors differed significantly.
Nerich
Virginie
V
Department of Pharmacy, University Hospital of Besançon, Besancon, 25030, France.
Tissot
Edgar
E
Faradji
Albert
A
Demesmay
Karine
K
Bertrand
Marie Anne
MA
Lorenzini
Jean-Louis
JL
Briquel
Marie-Elisabeth
ME
Pouzol
Patricia
P
Woronoff-Lemsi
Marie-Christine
MC
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003625:Data Collection; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D005164:Factor IX / Q000191:economics / Q000627:therapeutic use; D005169:Factor VIII / Q000191:economics / Q000627:therapeutic use; D005260:Female; D005602:France / Q000453:epidemiology; D006467:Hemophilia A / Q000188:drug therapy / Q000191:economics* / Q000628:therapy*; D002836:Hemophilia B / Q000188:drug therapy / Q000191:economics* / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D012189:Retrospective Studies; D012959:Socioeconomic Factors
D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX